Alumis Inc. Common Stock
NASDAQ:ALMS · NASDAQ Global Select
+$0.21 today
Vol 1.77M · Avg 1.31M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:ALMS · Revenue to Net Income
Key Ratios
Analysis
$8.4M of revenue converted into -$237.4M of net income for the selected period. Gross margin is 87.5% and net margin is -3324.5%, showing how much revenue survives after costs and taxes. EPS is $-1.92, tying the income statement back to per-share earnings.
Income Statement
Annual data · 4 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $24.1M | $0 | $0 | $0 | $1.0B | $809.6M | $921.6M |
| Cost of Revenue | $3.5M +10.9% | $3.2M | $0 -100.0% | $250.0K | $344.8M | $725.6M | $804.0M |
| Gross Profit | $20.6M +752.1% | -$3.2M | $0 +100.0% | -$250.0K | $10.3B | $8.9B | $7.6B |
| Gross Margin | 85.5% | — | — | — | 45.5% | 9.8% | 28.9% |
| Research & Development | $386.0M +45.4% | $265.6M +92.9% | $137.7M +36.2% | $101.1M | $378.4M | $983.2M | $1.3B |
| Selling, General & Admin | $91.9M +161.0% | $35.2M +71.7% | $20.5M +63.4% | $12.5M | $1.4B | $620.6M | $923.0M |
| Operating Expenses | $447.8M +50.5% | $297.6M +88.1% | $158.2M +39.2% | $113.6M | $3.6B | $5.3B | $7.0B |
| Depreciation & Amortization | $3.5M +10.9% | $3.2M +145.5% | $1.3M +413.6% | $250.0K | $1.2B | $374.2M | $1.2B |
| EBITDA | -$248.4M +14.7% | -$291.1M -89.4% | -$153.7M -37.6% | -$111.7M | $12.6B | -$15.2B | $6.8B |
| EBITDA Margin | -1032.8% | — | — | — | 10.0% | 5.6% | 46.3% |
| Operating Income | -$427.2M -42.0% | -$300.8M -90.1% | -$158.2M -38.9% | -$113.8M | $10.6B | $12.3B | $14.0B |
| Operating Margin | -1776.3% | — | — | — | 18.7% | 16.6% | 24.1% |
| Interest Income | $14.2M +18.0% | $12.0M +256.9% | $3.4M +69.1% | $2.0M | $1.3B | -$1.5B | -$1.6B |
| Interest Expense | $0 | $0 | $0 | $0 | $969.2M | $1.1B | $1.0B |
| Other Income / Expenses | $175.3M +2588.5% | $6.5M +105.0% | $3.2M +65.7% | $1.9M | -$1.6B | -$1.5B | $1.4B |
| Income Before Tax | -$251.9M +14.4% | -$294.2M -89.8% | -$155.0M -38.5% | -$111.9M | -$15.6B | $3.3B | $4.9B |
| Pre-Tax Margin | -1047.3% | — | — | — | 13.3% | 20.8% | 18.7% |
| Income Tax Expense | -$8.6M | $0 | $0 | $0 | $666.8M | $1.3B | -$1.6B |
| Net Income | -$243.3M +17.3% | -$294.2M -89.8% | -$155.0M -38.5% | -$111.9M | $5.0B | $4.9B | $4.8B |
| Net Margin | -1011.7% | — | — | — | 7.4% | 12.4% | 17.5% |
| EPS (Basic) | -$2 +77.6% | -$10 -247.2% | -$3 +80.0% | -$15 | $1.2B | $400.8M | $703.2M |
| EPS (Diluted) | -$2 +77.6% | -$10 -247.2% | -$3 +80.0% | -$15 | $620.6M | $766.2M | $609.4M |
| Weighted Avg Shares | $850.3M +2900.2% | $28.3M -45.3% | $51.8M +591.5% | $7.5M | $892.2M | $757.8M | $925.8M |
| Weighted Avg Shares (Diluted) | $850.3M +2900.1% | $28.3M -45.3% | $51.8M +591.5% | $7.5M | $319.6M | $1.2B | $924.4M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
RAPT Therapeutics, Inc.
RAPT
$959.26M
Lexicon Pharmaceuticals, Inc.
NASDAQ:LXRX
$890.61M
Eton Pharmaceuticals, Inc.
NASDAQ:ETON
$873.15M
Omeros Corporation
NASDAQ:OMER
$722.67M
Ocugen, Inc.
NASDAQ:OCGN
$432.29M
Lineage Cell Therapeutics, Inc.
AMEX:LCTX
$310.38M
Bicycle Therapeutics plc
NASDAQ:BCYC
$279.66M
Neumora Therapeutics, Inc. Common Stock
NASDAQ:NMRA
$272.37M
Fulcrum Therapeutics, Inc.
NASDAQ:FULC
$189.39M
ADC Therapeutics S.A.
NYSE:ADCT
$134.82M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does ALMS generate?
Alumis Inc. Common Stock (ALMS) reported $24.05M of revenue in fiscal 2025.
Is ALMS profitable?
Alumis Inc. Common Stock (ALMS) reported -$243,325,000.00 of net income, with a net margin of -1011.7%.
Explore More
Continue the stock analysis
Jump to another research area for this company.